Cardiff Oncology (NASDAQ:CRDF – Free Report) had its target price boosted by Piper Sandler from $7.00 to $10.00 in a report issued on Friday morning,Benzinga reports. They currently have an overweight rating on the stock.
CRDF has been the subject of a number of other research reports. Craig Hallum started coverage on Cardiff Oncology in a research report on Friday, September 6th. They set a “buy” rating and a $8.00 price target for the company. HC Wainwright lowered their target price on shares of Cardiff Oncology from $14.00 to $13.00 and set a “buy” rating on the stock in a research note on Friday, November 8th.
Get Our Latest Stock Report on Cardiff Oncology
Cardiff Oncology Stock Performance
Insider Buying and Selling at Cardiff Oncology
In other news, Director Gary W. Pace acquired 350,115 shares of Cardiff Oncology stock in a transaction dated Wednesday, December 11th. The shares were purchased at an average cost of $2.60 per share, for a total transaction of $910,299.00. Following the transaction, the director now owns 1,047,876 shares of the company’s stock, valued at $2,724,477.60. This trade represents a 50.18 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 7.80% of the company’s stock.
Institutional Trading of Cardiff Oncology
Several hedge funds and other institutional investors have recently bought and sold shares of CRDF. Assenagon Asset Management S.A. raised its stake in shares of Cardiff Oncology by 380.6% during the second quarter. Assenagon Asset Management S.A. now owns 1,215,922 shares of the company’s stock worth $2,699,000 after acquiring an additional 962,940 shares in the last quarter. Blair William & Co. IL grew its holdings in shares of Cardiff Oncology by 32.2% during the 2nd quarter. Blair William & Co. IL now owns 227,630 shares of the company’s stock valued at $505,000 after purchasing an additional 55,450 shares during the last quarter. Point72 DIFC Ltd purchased a new position in Cardiff Oncology in the 2nd quarter worth $27,000. GSA Capital Partners LLP lifted its stake in Cardiff Oncology by 432.7% in the third quarter. GSA Capital Partners LLP now owns 186,650 shares of the company’s stock worth $498,000 after purchasing an additional 151,613 shares during the last quarter. Finally, Rhumbline Advisers purchased a new stake in Cardiff Oncology during the second quarter valued at about $102,000. Hedge funds and other institutional investors own 16.29% of the company’s stock.
Cardiff Oncology Company Profile
Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.
See Also
- Five stocks we like better than Cardiff Oncology
- Are Penny Stocks a Good Fit for Your Portfolio?
- Dave & Buster’s: Is It Time to Make Another Play on This Stock?
- Roth IRA Calculator: Calculate Your Potential Returns
- Why Hershey Stock Has More Room to Run Despite Takeover Rejection
- How Technical Indicators Can Help You Find Oversold Stocks
- Texas Instruments: The Old-School Tech Titan Still Delivering
Receive News & Ratings for Cardiff Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiff Oncology and related companies with MarketBeat.com's FREE daily email newsletter.